Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: results of a randomised single heterologous booster dose study at 15 months.
Risi G, Frenette L, Langley JM, Li P, Riff D, Sheldon E, Vaughn DW, Fries L. Risi G, et al. Among authors: sheldon e. Vaccine. 2011 Aug 26;29(37):6408-18. doi: 10.1016/j.vaccine.2011.04.072. Epub 2011 May 7. Vaccine. 2011. PMID: 21554915 Clinical Trial.
Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study.
Langley JM, Risi G, Caldwell M, Gilderman L, Berwald B, Fogarty C, Poling T, Riff D, Baron M, Frenette L, Sheldon E, Collins H, Shepard M, Dionne M, Brune D, Ferguson L, Vaughn D, Li P, Fries L. Langley JM, et al. Among authors: sheldon e. J Infect Dis. 2011 Jun 15;203(12):1729-38. doi: 10.1093/infdis/jir172. J Infect Dis. 2011. PMID: 21606531 Free PMC article. Clinical Trial.
Immunological priming induced by a two-dose series of H5N1 influenza antigen, administered alone or in combination with two different formulations of AS03 adjuvant in adults: Results of a randomised single heterologous booster dose study at 15 months.
Risi G, Frenette L, Langley JM, Li P, Riff D, Sheldon E, Vaughn DW, Fries L. Risi G, et al. Among authors: sheldon e. Vaccine. 2013 Jan 2;31(2):436-7. doi: 10.1016/j.vaccine.2012.11.002. Vaccine. 2013. PMID: 23387064 Clinical Trial. No abstract available.
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V. Kieninger D, et al. Among authors: sheldon e. BMC Infect Dis. 2013 Jul 24;13:343. doi: 10.1186/1471-2334-13-343. BMC Infect Dis. 2013. PMID: 23883186 Free PMC article. Clinical Trial.
A phase 1a, first-in-human, randomized study of a respiratory syncytial virus F protein vaccine with and without a toll-like receptor-4 agonist and stable emulsion adjuvant.
Falloon J, Ji F, Curtis C, Bart S, Sheldon E, Krieger D, Dubovsky F, Lambert S, Takas T, Villafana T, Esser MT. Falloon J, et al. Among authors: sheldon e. Vaccine. 2016 May 27;34(25):2847-54. doi: 10.1016/j.vaccine.2016.04.002. Epub 2016 Apr 19. Vaccine. 2016. PMID: 27102821 Free article. Clinical Trial.
Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults.
Hopkins RJ, Kalsi G, Montalvo-Lugo VM, Sharma M, Wu Y, Muse DD, Sheldon EA, Hampel FC, Lemiale L. Hopkins RJ, et al. Vaccine. 2016 Apr 19;34(18):2096-105. doi: 10.1016/j.vaccine.2016.03.006. Epub 2016 Mar 12. Vaccine. 2016. PMID: 26979136 Free PMC article. Clinical Trial.
118 results